Harvard Bioscience Inc (NASDAQ:HBIO) currently has a daily average trading volume of 644.50K but it saw 1418327 shares traded in last market. With a market cap of 12.57M USD, the company’s current market price of $0.28 came falling about -23.84 while comparing to the previous closing price of $0.37. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.60 and as low as $0.29.
The Benchmark Company upgraded its recommendation for the stock as a “Buy” from “Speculative Buy” on March 10, 2023 while assigning a price target range of $3-$4.
Over the week, HBIO’s stock price is moving -15.49% down while it is -25.67% when we observe its performance for the past one month. Year-to-date it is -86.53% down and over the past year, the stock is showing a downside performance of -91.06%.
The company is expected to be releasing its next quarterly report in June, for which analysts forecasted an EPS of -0.03 while estimate for next year EPS is 0.04. In next quarter, company is expected to be making quarterly sales of $21.5M as analysts are expecting the sales for current fiscal year at $86.5M and seeing the company making $95.15M in sales next year. Moreover, analysts are in estimates of $18.75M for current-quarter revenue.
Currently, Harvard Bioscience Inc’s total number of outstanding shares is 44.21M with 8.27% of that held by the insiders while 71.44% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -263.09% and return on equity (ROE) at -138.80%. It has a 4.74 of forward P/E ratio. Stock’s beta reads 1.38. Stock has a price to book (P/B) ratio of 0.85 while price to sale or P/S ratio amounts to 0.14. Its return on asset (ROA) is -54.52% on average.
